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Abstract
Objective: Growing evidences indicate that the histone methyltransferase EZH2 (enhancer of zeste homolog 2) may be an
appropriate therapeutic target in some tumors. Indeed, a high expression of EZH2 is correlated with poor prognosis and
metastasis in many cancers. In addition, 3-Deazaneplanocin A (DZNep), an S-adenosyl-L homocysteine hydrolase inhibitor
which induces EZH2 protein depletion, leads to cell death in several cancers and tumors. The aim of this study was to
determine whether an epigenetic therapy targeting EZH2 with DZNep may be also efficient to treat chondrosarcomas.
Methods: EZH2 expression was determined by immunohistochemistry and western-blot. Chondrosarcoma cell line CH2879
was cultured in the presence of DZNep, and its growth and survival were evaluated by counting adherent cells periodically.
Apoptosis was assayed by cell cycle analysis, Apo2.7 expression using flow cytometry, and by PARP cleavage using western-
blot. Cell migration was assessed by wound healing assay.
Results: Chondrosarcomas (at least with high grade) highly express EZH2, at contrary to enchondromas or chondrocytes. In
vitro, DZNep inhibits EZH2 protein expression, and subsequently reduces the trimethylation of lysine 27 on histone H3
(H3K27me3). Interestingly, DZNep induces cell death of chondrosarcoma cell lines by apoptosis, while it slightly reduces
growth of normal chondrocytes. In addition, DZNep reduces cell migration.
Conclusion: These results indicate that an epigenetic therapy that pharmacologically targets EZH2 via DZNep may
constitute a novel approach to treat chondrosarcomas.
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Introduction
Polycomb group proteins (PcGs) can remodel chromatin by
influencing the degree of compaction, leading to epigenetic gene
silencing. In particular, EZH2, the catalytic subunit of Polycomb
Repressive Complex 2 (PRC2), induces histone methyltransferase
activity primarily by trimethylating histone H3 at lysine 27
(H3K27me3), hence mediating gene silencing. PcGs are crucial in
the chromatin control of stem cell self-renewal and differentiation
[1–7]. They also play a crucial role in malignant progression and
are implicated in cancer metastasis [8]. In particular, the
methylase EZH2 functions as an oncogene in different human
cancers mainly through epigenetic silencing of tumor and
metastasis suppressor genes, including E-cadherin [9], RUNX3
[10], SLIT2 [11], DAB2IP [12], FBXO32 [13], and KLF2 [14].
Recent articles showed that EZH2 knockdown results in a
significant decrease in cellular proliferation and invasiveness [15–
18], leading to emerge the concept of epigenetic therapy targeting
PcG machinery to cure various tumors, and the development of
drugs inhibiting the trimethylation of the lysine 27 on histone 3
(H3K27me3) [19–23].
Recently, it has been shown that 3-deazaneplanocin A
(DZNep), a carbocyclic analog of adenosine, depletes cellular
levels of the PRC2 components, and notably EZH2, and inhibits
H3K27me3 [13]. Interestingly, similarly to EZH2 knockdown,
DZNep reverts epithelial-to-mesenchymal transition (EMT), and
prevents tumor progression, making it a highly promising
antimetastatic agent [24]. While the mechanisms and effects of
DZNep have been studied in numerous solid tumors and leukemia
[13,25–33], less is known about the potential of this compound for
sarcomas. In particular its impact on chondrosarcoma, a radio-
and chemo-resistant tumor, has never been studied.
Here, we show that high grade chondrosarcomas express EZH2
protein, and that DZNep reduces its expression and subsequently
H3K27me3. Interestingly, DZNep treatment induces apoptosis of
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chondrosarcoma cell lines whereas it has a weak effect on normal
chondrocyte, and reduces cell migration, suggesting that targeting
EZH2, for instance using DZNep, may be an innovative
therapeutic strategy to treat chondrosarcomas.
Material and Methods
Reagents
DZNep was provided by R&D Biosystems (Lille, France) and
resuspended in phosphate buffered saline (PBS). Inhibitors and
propidium iodide were purchased from Sigma and dissolved in
PBS. Oligonucleotides were supplied by Eurogentec (Angers,
France).
Human material
This study was approved by the local ethic committee (Comite´
de protection des personnes Nord Ouest III). Tumoral and normal
cartilage was collected from surgical departments of Caen
University hospital. All donors signed agreement forms before
the surgery, according to local legislations.
Immunohistochemistry
Multiple specimens of chondrosarcomas (n = 7) or enchondro-
mas (n = 8) were fixed, routinely processed and embedded in
paraffin. H&E-stained sections from original block were used to
select a representative tumor area. 4-mm sections of non-
decalcified chondrosarcomas were prepared from paraffin-embed-
ded tumor blocks and placed on superfrost plus slides. After
antigen retrieval with pH 6.0 citrate buffer, immunohistochemis-
try was performed using an automated immunohistochemical
staining processor (Autostainer plus, Dako, Glostrup, Denmark).
After incubation with primary antibody EZH2 (Cell signaling,
1:100), detection was performed using an indirect biotin avidin
system, LSABTM2 detection kit (Dako) according to the
manufacturer’s instructions.
Cell culture
SW1353 (from ATCC) and CH2879 chondrosarcoma cell line
[34] were cultured in Dulbecco’s Modified Eagle Medium
(DMEM), or Roswell Park Memorial Institute 1640’s medium
(RPMI 1640) (Lonza AG, Verviers, Belgium), respectively,
supplemented with 10% fetal bovine serum (FBS) (Lonza AG),
0.25 mg/ml of fungizone and 10 mM of ciprofloxacin, and then
incubated at 37uC in a humidified atmosphere containing 5%
CO2. Cells were passaged twice a week. Cells were seeded for
experiments at 5400 cells/cm2 unless indicated otherwise.
The normal cartilage was obtained from biopsy of nasal
cartilage. Chondrocytes were released by digestion with XIV
Pronase (2 mg/ml for 30 minutes, Sigma-Aldrich, St Quentin
Fallavier, France) and type I collagenase (2 mg/ml for 15 hours,
Invitrogen, Cergy-Pontoise, France). The cells were incubated in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented
with 10% FBS, 0.25 mg/ml fungizone and 10 mM of ciprofloxacin,
and then incubated at 37uC in a humidified atmosphere
containing 5% CO2.
Protein extraction and Western blot
Cells were rinsed with phosphate buffered saline (PBS) to
remove residual FBS and scraped into RIPA lysis buffer (Tris-HCl
50 mM pH 7,5; IGEPAL 1%; NaCl 150 mM; EGTA 1 mM; NaF
1 mM) supplemented with phosphatase (NA3VO4 10 mL/ml) and
protease inhibitors (leupeptin 1 ml/ml, aprotinin 1 ml/ml, pep-
statin 1 ml/ml and phenylmethylsulfonyl fluoride 4 ml/ml). Pro-
teins (20 to 50 mg) were resolved by SDS-PAGE and transferred to
polyvinylidene difluoride membranes (Bio-Rad). The membranes
were incubated with 10% nonfat milk or 1% bovin serum albumin
(BSA) 1 hour at room temperature, incubated with primary
antibodies overnight at 4uC at the appropriated dilutions (EZH2,
1:1000 dilution, Cell signaling, catalog no. 5246; PARP, 1:1000
dilution, Cell signaling, catalog no. 9542; H3K27me3, 1:1000
dilution, Abcam, catalog no. ab6002; actin, 1:200 dilution, Santa
cruz biotechnology, catalog no. sc-8432; H3, 1:2000 dilution,
Abcam, catalog no. ab1791). The membranes were washed with
TBS-T and probed with a corresponding secondary antibody
conjugated to horsoradish peroxydase in TBS-T at room
temperature (goat anti-mouse IgG-HRP and goat anti-rabbit
IgG-HRP, 1:10000, Santa cruz biotechnology). Signals were
revealed with Western Lightning H Plus-ECL (Perkin Elmer) and
exposed to X-ray film (Kodak). Actin or histone H3 were used to
verify that similar amounts of protein were loaded in all lanes.
RNA isolation and real-time reverse transcription-
polymerase chain reaction (RT-PCR)
Total RNA was extracted with Trizol reagent according to the
manufacturer’s condition (Invitrogen). Samples (2 mg) were treated
with DNAse I (Invitrogen, Cergy-Pontoise, France) and the reverse
transcriptase was effected with oligo dT and Moloney murine
leukemia virus reverse transcriptase. Complementary DNA was
diluted (1:100) and stocked at 220uCpending for PCR. This
product (5 mL) was mixed with appropriated reverse and forward
primers and SYBR Green PCR Master Mix (Applied Biosystems,
Villebon sur Yvette, France) in 15 mL volume final. RT-PCR was
run in an ABI Prism 7000 sequence detection system apparatus.
Relative expression was calculated according to the 22DDCt
method [35].
Cell growth experiment
Cells were seeded at 750 cells/cm2 and treated with DZNep
(1 mM) for 14 days. The medium was changed twice during the
treatment. Adherent cells were counted each indicated time (4, 7,
9, 14 days).
Flow cytometry
Cells were treated with DZNep (1 mM) for 7 days. Then, cells
were washed with PBS, treated with trypsin-EDTA (Lonza AG,
Verviers, Belgium) and fixed with 70% ethanol at 220uC and
conserved at 4uC. For analysis, cells were washed twice with PBS
and resuspended in 20 mg/ml RNase (Invitrogen, Cergy-Pontoise,
France) and 50 mg/ml propidium iodide (IP) (Sigma Aldrich, St
Quentin Fallavier, France) to label the DNA. DNA content was
measured using Gallios (Beckman Coulter, Villepinte, France) on
the technical platform of SFR 146 (Structure Federative de
Recherche 146, Caen, France). Results were analyzed with Kaluza
software.
To study apoptosis, living cells were stained with Apo 2.7-PE
antibody according to the manufacturer’s condition (Beckman
Coulter, Villepinte, France). The expression of Apo 2.7 was
detected using Gallios on the technical platform of the SFR 146.
Wound healing assay
Cells were seeded at 40000 cells/cm2, treated with DZNep
(1 mM) for 5 days. At day 4, a straight scratch was made with a
200 ml pipette tip and the wound was photographed under the
microscope. After 24 h, cells were stained with crystal violet 0.1%
for 10 minutes and photographed under the microscope. The area
of the remaining scratch was calculated using Image J software
(http://rsb.info.nih.gov/ij/).
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Statistical analysis
For in vitro experiments, three different experiments were
performed. The values are means 6 SEM. Statistical significancy
was calculated with Student’s t test.
Results
EZH2 is expressed in chondrosarcomas
First, we investigated whether EZH2 is expressed in chondro-
sarcomas. Immunohistochemistry analysis from patient biopsies
showed that EZH2 is expressed in nucleus of high grade
chondrosarcomas (for 6/7 samples). Interestingly, we could not
detect EZH2 in all enchondromas tested (n = 8) (figure 1A).
Furthermore, by Western-Blot, we found that EZH2 expression
was higher in chondrosarcoma cells than normal chondrocytes
(figure 1B). Since EZH2 is highly expressed in chondrosarcomas,
we hypothesized that these tumors may be a sensitive to EZH2
inhibitors, such as DZNep.
DZNep inhibits EZH2 and reduces H3K27me3
As expected, DZNep treatment reduced EZH2 protein level,
and subsequently H3K27me3 level in two chondrosarcoma cell
lines, CH2879 and SW1353 (figure 2A and B). To investigate
whether decreased levels of EZH2 protein resulted from
transcriptional regulation, we performed quantitative real time-
PCR analysis. DZNep treatment had no effect on EZH2
expression at mRNA level (figure 2C).
DZNep selectively induces cytotoxicity in cancerous but
not normal cartilage cells
Furthermore, we evaluated the effect of DZNep treatment on
growth of chondrosarcoma cells and chondrocytes. DZNep
induced death of chondrosarcoma cells with a delay (figure 3A),
whereas it slightly decreased chondrocyte growth (figure 3B).
These results confirm the potential therapeutic of DZNep on
chondrosarcoma.
Figure 1. EZH2 is expressed in chondrosarcoma. A. EZH2 expression was analyzed by immunostaining in enchondromas (n = 8) (A1), or grade 2
and 3 chondrosarcomas (n = 7; 6 samples were positive for EZH2 staining) (A2 and A3 respectively). B. EZH2 expression was analyzed in two batches
of both SW1353 and CH2879 chondrosarcoma cell lines and normal chondrocytes by Western blot. Actin was used to compare protein loading.
doi:10.1371/journal.pone.0098176.g001
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DZNep induces apoptosis in chondrosarcomas
We then examined whether DZNep affects cell cycle. DZNep
treatment increased sub-G1 peak, without visible arrest in cell
cycle (figure 4A). DZNep also induced PARP cleavage and Apo
2.7 protein expression (figures 4 B and C) demonstrating an
apoptotic death of chondrosarcomas.
DZNep reduces cell migration
Finally, the effect of DZNep on migration was also examined by
wound healing assay (figure 5). We found that compared to
control, DZNep reduced the migration of chondrosarcomas.
Figure 2. DZNep reduces EZH2 protein expression and H3K27me3 and but not mRNA. SW1353 and CH2879 cells were treated with
DZNep (1 mM) for 72 h. A) EZH2 protein expression was analyzed by Western blot. Histograms represent the quantification of three independent
experiments after normalization with actin. B) H3K27me3 was also analyzed by Western blot. H3 was used to compare protein loading. Histograms
represent the quantification of three independent experiments after normalization with H3. C) EZH2 mRNA expression was analyzed by RT-PCR from
CH2879 treated with DZNep for 72 h. Data were expressed as means 6 SEM.
doi:10.1371/journal.pone.0098176.g002
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Discussion
With the advent of systemic chemotherapy in the management
of mesenchymal malignancies such as osteosarcoma and Ewing’s
sarcoma, there has been an increase in the long-term survival of
patients. In contrast, chondrosarcomas continue to have a poor
prognosis owing to the absence of an effective therapy [36–38].
Identifying new drugs that enables to reduce chondrosarcoma
growth may improve survival of patients. Here, we identified, 3-
Deazaneplanocin A (DZNep), a small molecule EZH2 inhibitor
[13,39], as a putative treatment of chondrosarcomas. Indeed, we
show that DZNep treatment significantly reduces the EZH2
protein and H3K27 trimethylation level, and induces chondro-
sarcoma death by apoptosis while it decreases their migration
ability.
First, we showed for the first time, that human chondrosarco-
mas, but not enchondromas, express EZH2 protein. In addition,
EZH2 level was more elevated in a grade II and III chondrosar-
coma cell lines, SW1353 and CH2879, than in chondrocytes. This
agrees with observations in other tumors showing that EZH2 is
overexpressed in cancers, including melanoma, lymphoma, and
breast and prostate cancers [13,27,33,40]. This high expression of
EZH2 is related to poor prognostic in these cancers and tumors
[8,41,42]. The potential use of EZH2 expression for improving
diagnostic of chondrosarcomas and the correlation between its
expression and tumor grade or prognostic for patients is still in
process.
Furthermore, we show for the first time that DZNep is efficient
to reduce chondrosarcoma growth, survival and migration, in vitro.
Numerous studies suggest that DZNep induces death in tumoral
cells though EZH2 downregulation and H3K27me3 reduction
[13,30,31,43]. In our chondrosarcoma model, we also found that
DZNep reduces EZH2 at protein level (but not at mRNA level)
and subsequently decreases H3K27me3. This discrepancy be-
tween mRNA and protein levels has ever been observed with other
tumoral cells [13,44], and can be explained by the mechanism by
which DZNep acts on EZH2. Indeed, DZNep acts indirectly by
inhibiting an S-adenosylhomocysteine (SAH) hydrolase, which
induce an accumulation of SAH, leading to the degradation of
EZH2 protein [39].
However, at this point, we cannot ascertain that chondrosar-
coma death induced by DZNep is directly due to EZH2 inhibition.
Indeed, DZNep is an AdoHcy hydrolase inhibitor and is able to
inhibit methylation of another repressive histone marks, such as
H4-K20 methylation [13]. More recently, it has been reported, in
MCF7 cells, that DZNep also causes a global decrease in most
histone modifications, except for H3K9me3 and H3K37me3,
implicating that DZNep is effective in decreasing histone
modifications with both repressive and active chromatin markers,
Figure 3. DZNep induces death in chondrosarcoma but not chondrocytes. CH2878 cells (A), SW1353 (B), or chondrocytes (C) were treated
with DZNep (1 mM) for 14 days. Treatment was renewed at each medium changes (at days 4, 7 and 10), and adherent cells regularly counted. The
results of three independent experiments are shown. Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0098176.g003
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in a non-selective manner [39,45]. Therefore, the molecular
mechanisms of DZNep might be more complex than our current
knowledge base, which associates the downregulation of EZH2
with the ability of DZNep to induce tumor cell death.
Contrary to the majority of tumoral cells, we found that DZNep
exerts cytotoxicity in chondrosarcomas with a delay. This was also
observed in pancreatic tumors [46]. However, similarly to a
number of tumor cells, we found that DZNep induced apoptosis in
chondrosarcomas, suggesting that the mechanism of death is
shared with all tumors cells, whereas here the effect was delayed.
We hypothesize that this delay may be due to a slower
proliferation kinetic of chondrosarcomas compared to other
tumoral cells. Interestingly, normal chondrocytes only show a
slight decrease of their growth upon DZNep treatment. Similarly,
other report also show that DZNep does not induce apoptosis in
normal cells, making it a promising drug candidate for anti-cancer
treatment, in particular to treat radioresistant and chemoresistant
tumors such as chondrosarcomas.
In conclusion, in this study, we describe the effect of an AdoHcy
hydrolase inhibitor, DZNep, on EZH2 expression and subsequent
H3K27me3 in chondrosarcomas, as well as its ability to
preferentially induce death by apoptosis in tumoral cartilage cells
than normal chondrocytes.
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